Treatment of glioblastoma multiforme
Glioblastoma multiforme (GBM) is both the most common and most aggressive primary brain malignancy.1 Despite advances in treatment, prognosis remains poor, with patients surviving an average of 15-18 months from time of diagnosis.2 Given the nature of this malignancy, it is also associated with proportionately...
Read more
